Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes
MINNEAPOLIS, June 01, 2023 -- Panbela Therapeutics, Inc. , a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical... | June 1, 2023
Source: marketscreener.com